RxDoctor Payments Data

Andrew Schimel, MD

Ophthalmology · Miami, FLNPI 1174714836

Payments from drug & device makers

$320,069in general payments, 2019–2025

Across 683 payments — averaging $468.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Regeneron Healthcare Solutions, Inc.$291K
  • Novartis$20K
  • Alcon$1K
  • Bausch & Lomb Americas Inc.$1K
  • Mallinckrodt Hospital Products Inc.$840
  • Sun Pharmaceutical Industries Inc.$811
  • plus $5K from 31 others

What the payments were for

  • Consulting fees$50,27316%
  • Speaking & faculty fees$228,77871%
  • Travel & lodging$24,7378%
  • Food & beverage$16,1825%
  • Education$1000%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$320,069 in reported general payments places this provider in the 95th percentile of 1,405 ophthalmology providers in Florida.

See all ophthalmology providers in Florida

Medicare billing

Part B allowed, 2024
$2,708,085
Medicare patients
965
Services billed
18,158

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EyleaAflibercept71$224,264
Prednisolone Acetate203$6,801
Ketorolac Tromethamine40$1,462
Polymyxin B Sul-TrimethoprimPolymyxin B Sulf/Trimethoprim81$738
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha41$585
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat36$534
Latanoprost27$131

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Regeneron Healthcare Solutions, Inc.Eylea$290,544$224,26471 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,405 ophthalmology providers in Florida.

Other ophthalmology in Miami

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →